Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Apr 11, 2006
Trial Information
Current as of June 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Positive history of clinical stroke at least 4 months prior to randomization CPSP--3 months prior to screening
- Exclusion Criteria:
- • History of dementia or any other severe cognitive impairment
- • Diabetic Peripheral Neuropathy (DPN)
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manila, , Philippines
New Territories, , Hong Kong
Darlinghurst, New South Wales, Australia
Perth, Western Australia, Australia
Seoul, , Korea, Republic Of
Kuala Lumpur, , Malaysia
Taipei, , Taiwan
St Leonards, New South Wales, Australia
Herston, Queensland, Australia
Jakarta, , Indonesia
Surabaya, , Indonesia
Bangkok, , Thailand
Taichung, , Taiwan
Warrawong, New South Wales, Australia
Beijing, , China
East Gosford, New South Wales, Australia
Footscray, Victoria, Australia
Penang, , Malaysia
Bangalore, , India
Lucknow, , India
New Delhi, , India
Guang Zhou, , China
Shang Hai, , China
Chennai, , India
Selangor, , Malaysia
Karachi, Sindh, Pakistan
Gueishan Shiang, Taoyuan Hsien, Taiwan
Ratchatewee, Bangkok, Thailand
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials